Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16261301 | 0.84 | CYP3A4 (0.51) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL4736745 | 0.84 | CA1 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28199606 | 0.82 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL16261206 | 0.80 | ALDH1A1 (0.47) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL12285360 | 0.77 | MAPT (0.53) | LMNASMN1; SMN2POLBCYP3A4MEN1 | |
| SCHEMBL16261204 | 0.76 | ALDH1A1 (0.54) | LMNASMN1; SMN2HTTPOLBGAA | |
| SCHEMBL813077 | 0.76 | CA1 (0.65) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL123883 | 0.74 | CA1 (1.00) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL12353346 | 0.74 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL812692 | 0.74 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| US-7453011-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6982351-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | CA1 1477/4885CA2 1766/4885MMP1 4739/4885 |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | CA1 2456/4885CA2 3641/4885MMP1 3282/4885 |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | CA1 2456/4885CA2 3641/4885MMP1 3282/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | CA1 2456/4885CA2 3641/4885MMP1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.